Total trials
180
Active
36
Phase 3
7
Total enrollment
15,384
Pipeline matrix
Showing 14 of 14 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| MitoQ | — | — | — | — | — | 1 | |
| D-Cycloserine | — | — | — | — | 4 | ||
| Cannabidiol | — | — | — | — | 4 | ||
| Nociceptin Receptor Antagonist | — | — | — | — | — | 2 | |
| Magnesium vitamin B6 | — | — | — | — | — | 1 | |
| Dextromethophan | — | — | — | — | — | 1 | |
| Suvorexant 20 mg | — | — | — | — | — | 1 | |
| Suvorexant 10 mg | — | — | — | — | — | 1 | |
| D-serine | — | — | — | — | — | 1 | |
| Lorazepam | — | — | — | — | 2 | ||
| high CBD/low THC sublingual solution | — | — | — | — | — | 1 | |
| Baclofen | — | — | — | — | — | 1 | |
| Memantine | — | — | 4 | ||||
| PET radiotracer | — | — | — | — | — | 1 |
Next readouts
- 2026-06
- 2026-07-31
- 2026-10
- 2026-10-28
- 2026-12
- 2026-12
- 2026-12-26
- 2027-01-31
- 2027-03-31
- 2027-06
Top conditions
- Major Depressive Disorder23
- Bipolar Disorder20
- Depression14
- Nicotine Dependence12
- Schizophrenia12
- Bipolar Depression12
- Schizoaffective Disorder9
- Psychosis9
Frequently asked questions about Mclean Hospital
- How many clinical trials does Mclean Hospital have on ClinicalTrials.gov?
- Mclean Hospital is listed as the lead sponsor on 180 clinical trials in ClinicalTrials.gov, 36 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Mclean Hospital's trials are in Phase 3?
- 7 of Mclean Hospital's trials are in Phase 3, spread across 14 active drug programs.
- What therapeutic areas does Mclean Hospital focus on?
- Mclean Hospital's most-studied conditions on ClinicalTrials.gov are Major Depressive Disorder, Bipolar Disorder, Depression, Nicotine Dependence, Schizophrenia.
- When are Mclean Hospital's next clinical trial readouts?
- Mclean Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis”, expected around 2026-06.